MorphoSys
A German, commercial-stage biopharmaceutical company developing monoclonal antibodies for therapeutic and research applications in the areas of cancer and autoimmune diseases.
Morphosys facillitates research and development activities by partnering with pharmaceutical and biotech companies.
In February 2924, the company announced that it was enterinf into a Business Combination Agreement with Novartis, which will see Novartis obtain exclusive, worldwide rights to develop and commercialize pelabresib, an investigational BET inhibitor, and tulmimetostat, an investigational next-generation dual inhibitor of EZH2 and EZH1, across all indications.
Latest MorphoSys News & Features
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze